Our mission is to make a meaningful difference in the lives of thousands of the most vulnerable infants through world class research and innovative products.
Prolacta Bioscience is a privately held, life sciences company dedicated to improving the quality of life in the most fragile infants through the harmony of nature and science. We create specialty formulations made from human milk for the nutritional needs of premature infants in neonatal intensive care units (NICU). These formulations are sold to NICUs around the country.
Prolacta developed the first large scale human milk processing facility in the world. Using state-of-the-art formulation, pasteurization and filling processes, we formulate human milk to an exact standard to meet the needs of very low birth weight babies during the first 30 days of life.
Prolacta is committed to supporting research in the study of human milk and premature infant nutrition in order to make a difference in the lives of the most fragile premature babies.
Better Health, Brighter Future
When Chobei Takeda I established his medicine distribution business in Osaka in 1781, he gained a reputation for his dedication to providing quality products and services. 235 years later, we feel great humility in knowing that from those modest beginnings our medicines, many of which continue to be manufactured here in Japan, now reach patients in over 70 countries and territories worldwide.
Knowing of the relief that a single medicine can have upon the lives of not only patients but entire families and communities, we are driven to pursue the discovery and development of new treatments.
Our scientists are assisted by the latest cutting edge technologies, and supported by the combined insights and experience of our entire research community.
We put the patient at the center of everything we do as we strive towards better health for people worldwide, through leading innovation in medicine.